European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis

On 18 September 2017, a marketing authorisation valid through the European Union (EU) was issued for midostaurin in combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy and for patients in complete response followed by midostaurin single...

Descripción completa

Detalles Bibliográficos
Autores principales: Tzogani, Kyriaki, Yu, Yang, Meulendijks, Didier, Herberts, Carla, Hennik, Paula, Verheijen, Remy, Wangen, Torunn, Dahlseng Håkonsen, Gro, Kaasboll, Torny, Dalhus, Marianne, Bolstad, Bjorg, Salmonson, Tomas, Gisselbrecht, Christian, Pignatti, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001097/
https://www.ncbi.nlm.nih.gov/pubmed/32392175
http://dx.doi.org/10.1136/esmoopen-2019-000606

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001097/
https://www.ncbi.nlm.nih.gov/pubmed/32392175
http://dx.doi.org/10.1136/esmoopen-2019-000606

Ejemplares similares